Search

Your search keyword '"Bontkes, Hetty J."' showing total 356 results
Start Over Author "Bontkes, Hetty J."
356 results on '"Bontkes, Hetty J."'

6. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

Author

Kant, Iris M.J., Graas, Thecla, Toussaint, Belle, de Jong, Sterre, Darwesh, Shahan, Mahes, Sandjiv S., Kamminga, Dora, Koelewijn, Matthijs, Faber, Gino, Beaumont, Guus, Engel, Marije D., Pierie, R. Cheyenne N., Janssen, Suzanne R., van Dijkman, Edith, Heijmans, Jarom, Witte, Yara Y., Nahui Palomino, Rogers A., Omar, Said Z., Zweegman, Sonja, Kater, Arnon P., van den Vegt, Caya, Arends-Halbesma, Ilonka, de Pater, Emma, Dijkstra, Margriet J., Rots, Nynke Y., Rijnstra, Esther Siteur-van, de Rooij, Dennis M., Sanders, Rogier W., Poniman, Meliawati, Olijhoek, Wouter, van Rijswijk, Jacqueline, Beaumont, Tim, Çetinel, Lusia, Schellekens, Louis, den Hartogh, Yvonne M., Cloos, Jacqueline, Weijers, Suzanne S., Tonouh-Aajoud, Saïda, Avci, Selime, Roelandse-Koop, Elianne, Dik, Willem A., Hofsink, Quincy, Haggenburg, Sabine, Lissenberg-Witte, Birgit I., Broers, Annoek E.C., van Doesum, Jaap A., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., van Meerloo, Johan, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby P., Wouters, Dorine, van Leeuwen, Ester M.M., Bontkes, Hetty J., Kootstra, Neeltje A., Vogels-Nooijen, Sandra, Rots, Nynke, van Beek, Josine, Heemskerk, Mirjam H.M., Groen, Kazimierz, van Meerten, Tom, Mutsaers, Pim G.N.J., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., and Nijhof, Inger S.

Published
2023
Full Text
View/download PDF

7. Enduring clinical remission in refractory celiac disease type II with tofacitinib: an open-label clinical study

Author

Dieckman, Tessa, primary, Schumann, Michael, additional, Beaumont, Hanneke, additional, Bontkes, Hetty J., additional, Koning, Frits, additional, Bouma, Gerd, additional, Byrnes, Valerie, additional, McCarthy, Jane, additional, Neefjes-Borst, Andra, additional, Loddenkemper, Christoph, additional, Weegh, Marlous op de, additional, and Lundin, K.E.A., additional

Published
2024
Full Text
View/download PDF

8. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

Author

Haggenburg, Sabine, Lissenberg-Witte, Birgit I., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., de Rooij, Dennis M., van Meerloo, Johan, Cloos, Jacqueline, Kootstra, Neeltje A., Wouters, Dorine, Weijers, Suzanne S., van Leeuwen, Ester M.M., Bontkes, Hetty J., Tonouh-Aajoud, Saïda, Heemskerk, Mirjam H.M., Sanders, Rogier W., Roelandse-Koop, Elianne, Hofsink, Quincy, Groen, Kazimierz, Çetinel, Lucia, Schellekens, Louis, den Hartog, Yvonne M., Toussaint, Belle, Kant, Iris M.J., Graas, Thecla, de Pater, Emma, Dik, Willem A., Engel, Marije D., Pierie, Cheyenne R.N., Janssen, Suzanne R., van Dijkman, Edith, Poniman, Meliawati, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby, Rots, Nynke Y., Zweegman, Sonja, Kater, Arnon P., van Meerten, Tom, Mutsaers, Pim G.N.J., van Doesum, Jaap A., Broers, Annoek E.C., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., and Nijhof, Inger S.

Published
2022
Full Text
View/download PDF

9. Monitoring patients with celiac disease on gluten free diet: different outcomes comparing three tissue transglutaminase IgA assays

Author

Mulder, A H Leontine, Castelijn, Daan A R, van der Pol, Pieter, Vermeer, Marloes, Hollander, Jolien C, Kuiper, Tietie, Bijnens, Caroline, Bontkes, Hetty J, Damoiseaux, Jan, Mulder, A H Leontine, Castelijn, Daan A R, van der Pol, Pieter, Vermeer, Marloes, Hollander, Jolien C, Kuiper, Tietie, Bijnens, Caroline, Bontkes, Hetty J, and Damoiseaux, Jan

Abstract

Objectives: Tissue transglutaminase (tTG) IgA antibodies are a hallmark for celiac disease (CD). In CD patients on gluten free diet (GFD) these antibodies are transient. Few studies are available comparing the tTG-IgA assay characteristics for monitoring response to GFD. Since discrepant results were reported in patients on GFD after switching tTG-IgA assays, we conducted a retrospective observational study to monitor GFD response using three different tTG-IgA assays. Methods: Diagnostic samples from 44 adults and 17 children with CD were included. Of most patients two follow-up samples after introduction of GFD were available. In all samples tTG-IgA were assessed using one fluorochrome-enzyme immuno-assay (FEIA) and two chemiluminescence immuno-assays (CLIA) and intestinal fatty acid binding protein (i-FABP) as surrogate marker for intestinal epithelial damage was measured. Results: Using CLIA assays, normalization of antibody levels was delayed compared to FEIA (p<0.001). Of all samples taken after at least 6months on GFD with elevated i-FABP indicating intestinal epithelial damage, 40% had positive tTG-IgA according to the FEIA, 85 and 90% according to the two CLIA. Conclusions: Normalization of tTG-IgA in patients on GFD depends on the assay used. Both CLIA appear to be more sensitive in detecting suboptimal treatment response in CD-indicated by elevated i-FABP - when applying the manufacturer's recommended cut-off for the diagnosis of CD.

Published
2024

12. Monitoring patients with celiac disease on gluten free diet: different outcomes comparing three tissue transglutaminase IgA assays.

Author

Mulder, A.H. Leontine, Castelijn, Daan A.R., van der Pol, Pieter, Vermeer, Marloes, Hollander, Jolien C., Kuiper, Tietie, Bijnens, Caroline, Bontkes, Hetty J., and Damoiseaux, Jan

Subjects
GLUTEN-free diet, CELIAC disease, IMMUNOGLOBULIN A, PATIENT monitoring, CARRIER proteins, GLIADINS
Abstract

Tissue transglutaminase (tTG) IgA antibodies are a hallmark for celiac disease (CD). In CD patients on gluten free diet (GFD) these antibodies are transient. Few studies are available comparing the tTG-IgA assay characteristics for monitoring response to GFD. Since discrepant results were reported in patients on GFD after switching tTG-IgA assays, we conducted a retrospective observational study to monitor GFD response using three different tTG-IgA assays. Diagnostic samples from 44 adults and 17 children with CD were included. Of most patients two follow-up samples after introduction of GFD were available. In all samples tTG-IgA were assessed using one fluorochrome-enzyme immuno-assay (FEIA) and two chemiluminescence immuno-assays (CLIA) and intestinal fatty acid binding protein (i-FABP) as surrogate marker for intestinal epithelial damage was measured. Using CLIA assays, normalization of antibody levels was delayed compared to FEIA (p<0.001). Of all samples taken after at least 6 months on GFD with elevated i-FABP indicating intestinal epithelial damage, 40 % had positive tTG-IgA according to the FEIA, 85 and 90 % according to the two CLIA. Normalization of tTG-IgA in patients on GFD depends on the assay used. Both CLIA appear to be more sensitive in detecting suboptimal treatment response in CD-indicated by elevated i-FABP – when applying the manufacturer's recommended cut-off for the diagnosis of CD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study

Author

Hofsink, Quincy, primary, Haggenburg, Sabine, additional, Lissenberg-Witte, Birgit I., additional, Broers, Annoek E.C., additional, van Doesum, Jaap A., additional, van Binnendijk, Rob S., additional, den Hartog, Gerco, additional, Bhoekhan, Michel S., additional, Haverkate, Nienke J.E., additional, van Meerloo, Johan, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, Smits, Gaby P., additional, Wouters, Dorine, additional, van Leeuwen, Ester M.M., additional, Bontkes, Hetty J., additional, Kootstra, Neeltje A., additional, Vogels-Nooijen, Sandra, additional, Rots, Nynke, additional, van Beek, Josine, additional, Heemskerk, Mirjam H.M., additional, Groen, Kazimierz, additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, van Gils, Marit J., additional, Goorhuis, Abraham, additional, Rutten, Caroline E., additional, Hazenberg, Mette D., additional, Nijhof, Inger S., additional, Kant, Iris M.J., additional, Graas, Thecla, additional, Toussaint, Belle, additional, de Jong, Sterre, additional, Darwesh, Shahan, additional, Mahes, Sandjiv S., additional, Kamminga, Dora, additional, Koelewijn, Matthijs, additional, Faber, Gino, additional, Beaumont, Guus, additional, Engel, Marije D., additional, Pierie, R. Cheyenne N., additional, Janssen, Suzanne R., additional, van Dijkman, Edith, additional, Heijmans, Jarom, additional, Witte, Yara Y., additional, Nahui Palomino, Rogers A., additional, Omar, Said Z., additional, Zweegman, Sonja, additional, Kater, Arnon P., additional, van den Vegt, Caya, additional, Arends-Halbesma, Ilonka, additional, de Pater, Emma, additional, Dijkstra, Margriet J., additional, Rots, Nynke Y., additional, Rijnstra, Esther Siteur-van, additional, de Rooij, Dennis M., additional, Sanders, Rogier W., additional, Poniman, Meliawati, additional, Olijhoek, Wouter, additional, van Rijswijk, Jacqueline, additional, Beaumont, Tim, additional, Çetinel, Lusia, additional, Schellekens, Louis, additional, den Hartogh, Yvonne M., additional, Cloos, Jacqueline, additional, Weijers, Suzanne S., additional, Tonouh-Aajoud, Saïda, additional, Avci, Selime, additional, Roelandse-Koop, Elianne, additional, and Dik, Willem A., additional

Published
2023
Full Text
View/download PDF

17. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI):a cohort study

Author

Hofsink, Quincy, Haggenburg, Sabine, Lissenberg-Witte, Birgit I., Broers, Annoek E.C., van Doesum, Jaap A., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., van Meerloo, Johan, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby P., Wouters, Dorine, van Leeuwen, Ester M.M., Bontkes, Hetty J., Kootstra, Neeltje A., Vogels-Nooijen, Sandra, Rots, Nynke Y., van Beek, Josine, Heemskerk, Mirjam H.M., Groen, Kazimierz, van Meerten, Tom, Mutsaers, Pim G.N.J., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., Nijhof, Inger S., Hofsink, Quincy, Haggenburg, Sabine, Lissenberg-Witte, Birgit I., Broers, Annoek E.C., van Doesum, Jaap A., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J.E., van Meerloo, Johan, Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby P., Wouters, Dorine, van Leeuwen, Ester M.M., Bontkes, Hetty J., Kootstra, Neeltje A., Vogels-Nooijen, Sandra, Rots, Nynke Y., van Beek, Josine, Heemskerk, Mirjam H.M., Groen, Kazimierz, van Meerten, Tom, Mutsaers, Pim G.N.J., van Gils, Marit J., Goorhuis, Abraham, Rutten, Caroline E., Hazenberg, Mette D., and Nijhof, Inger S.

Abstract

Background: Patients with haematological malignancies have impaired antibody responses to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 vaccination improved antibody quantity and quality. Methods: In this cohort study, conducted at 5 sites in the Netherlands, we compared antibody concentrations 28 days after 4 mRNA vaccinations (3-dose primary series plus 1 booster vaccination) in SARS-CoV-2 naive, immunocompromised patients with haematological malignancies to those obtained by age-matched, healthy individuals who had received the standard primary 2-dose mRNA vaccination schedule followed by a first booster mRNA vaccination. Prior to and 4 weeks after each vaccination, peripheral blood samples and data on demographic parameters and medical history were collected. Concentrations of antibodies that bind spike 1 (S1) and nucleocapsid (N) protein of SARS-CoV-2 were quantified in binding antibody units (BAU) per mL according to the WHO International Standard for COVID-19 serological tests. Seroconversion was defined as an S1 IgG concentration >10 BAU/mL and a previous SARS-CoV-2 infection as N IgG >14.3 BAU/mL. Antibody neutralising activity was tested using lentiviral-based pseudoviruses expressing spike protein of SARS-CoV-2 wild-type (D614G), Omicron BA.1, and Omicron BA.4/5 variants. This study is registered with EudraCT, number 2021-001072-41. Findings: Between March 24, 2021 and May 4, 2021, 723 patients with haematological diseases were enrolled, of which 414 fulfilled the inclusion criteria for the current analysis. Although S1 IgG concentrations in patients significantly improved after the fourth dose, they remained significantly lower compared to those obtained by 58 age-matched healthy individuals after their first booster (third) vaccination. The rise in neutralising antibody concentration was most prominent in patients with a recovering B cell compartment, although potent responses were also observed in patients with

Published
2023

19. Systemische neuroimmuun responsen bij patienten met persisterende nekpijn en cervicale radiculopathie, en associaties met klinische, psychologische en leefstijl factoren

Author

Lutke Schipholt, Ivo, Coppieters, Michel, Bontkes, Hetty J., Scholten-Peeters, Wendy GM, Neuromechanics, AMS - Rehabilitation & Development, and AMS - Musculoskeletal Health

Subjects
SDG 3 - Good Health and Well-being
Abstract

Pijn is een complex fenomeen. Over het pathomechanisme van nekpijn en cervicale radiculopathie bestaat nog veel onduidelijkheid. Het neuro-immuunsysteem lijkt een belangrijke rol te spelen.

Published
2023

21. Fourth mRNA COVID-19 Vaccination in Immunocompromised Patients with Hematologic Malignancies

Author

Hofsink, Quincy, primary, Haggenburg, Sabine, additional, Lissenberg-Witte, Birgit I., additional, Broers, Annoek E.C., additional, van Doesum, Jaap A., additional, van Binnendijk, Robert Samuel, additional, den Hartog, Gerco, additional, Bhoekhan, Michel S., additional, Haverkate, Nienke J.E., additional, van Meerloo, Johan, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, Smits, Gaby, additional, Wouters, D., additional, van Leeuwen, Ester M.M., additional, Bontkes, Hetty J., additional, Kootstra, Neeltje A., additional, Vogels-Nooijen, Sandra, additional, Rots, Nynke, additional, van Beek, Josine, additional, Heemskerk, Mirjam HM, additional, Groen, Kazimierz, additional, van Meerten, Tom, additional, Mutsaers, Pim G. N. J., additional, van Gils, Marit J., additional, Goorhuis, Abraham, additional, Rutten, Caroline E., additional, Hazenberg, Mette D., additional, Nijhof, Inger S., additional, and Team, COBRA KAI Study, additional

Published
2023
Full Text
View/download PDF

23. Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Author

Pothast, Cilia R., primary, Hofsink, Quincy, additional, Haggenburg, Sabine, additional, Michel, Bhoekhan S., additional, Haverkate, Nienke J.E., additional, Dijkland, Romy C., additional, Van Dijk, Kayleigh, additional, Falkenburg, Frederik J.H., additional, Broers, Annoek E.C., additional, van Doesum, Jaap, additional, Van Binnendijk, Robert S., additional, Den Hartog, Gerco, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, Lissenberg-Witte, Birgit I., additional, Smits, Gaby P., additional, Wouters, Dorine, additional, van Leeuwen, Ester M.M., additional, Bontkes, Hetty J., additional, Kootstra, Neeltje A., additional, Zweegman, Sonja, additional, Kater, Arnon P., additional, Groen, Kaz, additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, Beaumont, Tim, additional, Van Gils, Marit J., additional, Goorhuis, Abraham, additional, Hazenberg, Mette D., additional, Nijhof, Inger S., additional, Heemskerk, Mirjam H.M., additional, and Rutten, Caroline E., additional

Published
2022
Full Text
View/download PDF

24. Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Author

Pothast, Cilia R., primary, Hofsink, Quincy, additional, Haggenburg, Sabine, additional, Bhoekhan, Michel, additional, Haverkate, Nienke J.E., additional, Dijkland, Romy C., additional, van Dijk, Kayleigh, additional, Falkenburg, Frederik J.H., additional, Broers, Annoek E.C., additional, van Doesum, Jaap, additional, van Binnendijk, Robert S., additional, den Hartog, Gerco, additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, Lissenberg-Witte, Birgit I., additional, Smits, Gaby P., additional, Wouters, Dorine, additional, van Leeuwen, Ester M.M., additional, Bontkes, Hetty J., additional, Kootstra, Neeltje A., additional, Zweegman, Sonja, additional, Kater, Arnon P., additional, Groen, Kaz, additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, Beaumont, Tim, additional, van Gils, Marit J., additional, Goorhuis, Abraham, additional, Hazenberg, Mette D., additional, Nijhof, Inger S., additional, Heemskerk, Mirjam H.M., additional, and Rutten, Caroline E., additional

Published
2022
Full Text
View/download PDF

33. Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients

Author

Haggenburg, Sabine, primary, Hofsink, Quincy, additional, Lissenberg-Witte, Birgit I., additional, Broers, Annoek E.C., additional, van Doesum, Jaap A., additional, van Binnendijk, Rob S., additional, den Hartog, Gerco, additional, Bhoekhan, Michel S., additional, Haverkate, Nienke J.E., additional, Burger, Judith A., additional, Bouhuijs, Joey H., additional, Smits, Gaby P., additional, Wouters, Dorine, additional, van Leeuwen, Ester M.M., additional, Bontkes, Hetty J., additional, Kootstra, Neeltje A., additional, Zweegman, Sonja, additional, Kater, Arnon P., additional, Heemskerk, Mirjam H.M., additional, Groen, Kaz, additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, Beaumont, Tim, additional, van Gils, Marit J., additional, Goorhuis, Abraham, additional, Rutten, Caroline E., additional, Hazenberg, Mette D., additional, and Nijhof, Inger S., additional

Published
2022
Full Text
View/download PDF

35. The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned

Author

Nagy, Eszter, primary, Infantino, Maria, additional, Bizzaro, Nicola, additional, Andreeva, Hristina, additional, Bontkes, Hetty J., additional, Bossuyt, Xavier, additional, Fabien, Nicole, additional, Fischer, Katarzyna, additional, Heijnen, Ingmar A.F.M., additional, Herold, Manfred, additional, Kozmar, Ana, additional, Kuhi, Liisa, additional, López-Hoyos, Marcos, additional, Pullerits, Rille, additional, Sousa, Maria José Rego, additional, Tsirogianni, Alexandra, additional, and Damoiseaux, Jan, additional

Published
2021
Full Text
View/download PDF

36. Pre-analytical sample handling effects on blood cytokine levels: Quality control of a COVID-19 biobank

Author

Verberk, Inge Mw, Nossent, Esther J., Bontkes, Hetty J., Teunissen, Charlotte E., Clinical chemistry, Pulmonary medicine, AII - Inflammatory diseases, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Neuroinfection & -inflammation, and Amsterdam Reproduction & Development (AR&D)

Abstract

Aim: We investigated the effect of pre-analytical sample handling variations on coronavirus disease 2019-relevant circulating cytokine levels IFN-γ, IL-10, IL-12p70, IL-17A, IL-6 and TNF-α. Materials & methods: We collected blood in different collection tubes (ethylenediaminetetraacetic acid, sodium citrate, lithium heparin, serum), and subjected ethylenediaminetetraacetic acid plasma to among others increasing delays in centrifugation or -80°C storage. Six subjects were included in each experimental condition. Cytokine levels were measured in these samples using the Simoa Cytokine 6-plex kit. Results: Different tube types resulted in different blood cytokine levels. IL-17A and IL-6 levels declined with 3 h centrifugation delay. IFN-γlevels declined with 24 h postcentrifugation storage delay. IL-17A levels declined with 2-week storage delay. Conclusion: It is recommended to centrifuge tubes quickly following collection, for accurate cytokine measurement.

Published
2021

38. Nickel allergy is associated with a broad spectrum cytokine response.

Author

De Graaf, Niels P. J., Roffel, Sanne, Gibbs, Susan, Kleverlaan, Cees J., Lopez Gonzalez, Marta, Rustemeyer, Thomas, Feilzer, Albert J., and Bontkes, Hetty J.

Subjects
MONONUCLEAR leukocytes, NICKEL, CYTOKINES, ALLERGIES
Abstract

Background: Nickel‐induced proliferation or cytokine release by peripheral blood mononuclear cells may be used for in vitro diagnosis of nickel allergy. Objectives: Aim of this study was to explore the nickel‐specific cytokine profile to further elucidate the pathogenesis of nickel allergic contact dermatitis (ACD) and to identify potential new biomarkers for nickel ACD. Methods: Peripheral blood mononuclear cells from patients and controls were cultured with T‐cell skewing cytokine cocktails and/or nickel. Cytokine and chemokine concentrations were assessed in culture supernatants using validated multiplex assays. Specific cytokine production was related to history of nickel allergy and patch‐test results. Results: Twenty‐one of the 33 analytes included in the analysis were associated with nickel allergy and included type1 (TNF‐α, IFN‐γ, TNF‐β), type 2 (IL‐3, IL‐4, IL‐5, IL‐13), type 1/2 (IL‐2, IL‐10), type 9 (IL‐9), type 17/1 (IL‐17A[F], GM‐CSF, IL‐21) and type 22 (IL‐22) derived cytokines as well as the T‐cell/antigen presentation cell derived factors Thymus and activation regulated chemokine (TARC), IL‐27 and IP‐10. Receiver operator characteristics (ROC) analysis showed that IL‐5 was the strongest biomarker for nickel allergy. Conclusions: A broad spectrum of 33 cytokines and chemokines is involved in the allergen‐specific immune response in nickel allergic patients. IL‐5 remains, next to the lymphocyte proliferation test, the strongest biomarker for nickel allergy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Systemic neuroimmune responses in people with non-specific neck pain and cervical radiculopathy, and associations with clinical, psychological, and lifestyle factors.

Author

Schipholt, Ivo J. Lutke, Scholten-Peeters, Gwendolyne G. M., Koop, Meghan A., Bonnet, Petra, Bontkes, Hetty J., and Coppieters, Michel W.

Subjects
NECK pain, RADICULOPATHY, PSYCHONEUROIMMUNOLOGY, LEUCOCYTES, ANALYSIS of covariance, ADIPOSE tissues
Abstract

Neuroimmune responses remain understudied in people with neck pain. This study aimed to (1) compare a broad range of systemic neuroimmune responses in people with non-specific neck pain (N = 112), cervical radiculopathy (N = 25), and healthy participants (N = 23); and (2) explore their associations with clinical, psychological and lifestyle factors. Quantification of systemic neuroimmune responses involved ex vivo serum and in vitro evokedrelease levels of inflammatory markers, and characterization of white blood cell phenotypes. Inflammatory indices were calculated to obtain a measure of total immune status and were considered the main outcomes. Differences between groups were tested using analyses of covariance (ANCOVA) and multivariable regression models. Compared to healthy participants, the ex vivo pro-inflammatory index was increased in people with non-specific neck pain (β = 0.70, p = 0.004) and people with cervical radiculopathy (β = 0.64, p = 0.04). There was no difference between non-specific neck pain and cervical radiculopathy (β = 0.23, p = 0.36). Compared to non-specific neck pain, people with cervical radiculopathy showed lower numbers of monocytes (β D -59, p = 0.01). There were no differences between groups following in vitro whole blood stimulation (p > 0.23) or other differences in the number and phenotype of white blood cells (p > 0.07). The elevated ex vivo neuroimmune responses in people with non-specific neck pain and radiculopathy support the contention that these conditions encompass inflammatory components that can be measured systemically. There were multiple significant associations with clinical, psychological and lifestyle factors, such as pain intensity (β = 0.25) and anxiety (β = 0.23) in non-specific neck pain, visceral adipose tissue (β = 0.43) and magnification (β = 0.59) in cervical radiculopathy, and smoking (β = 0.59) and visceral adipose tissue (β = 0.52) in healthy participants. These associations were modified by sex, indicating different neuroimmune associations for females and males. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.

Author

Haggenburg, Sabine, Hofsink, Quincy, Lissenberg-Witte, Birgit I., Broers, Annoek E. C., van Doesum, Jaap A., van Binnendijk, Rob S., den Hartog, Gerco, Bhoekhan, Michel S., Haverkate, Nienke J. E., Burger, Judith A., Bouhuijs, Joey H., Smits, Gaby P., Wouters, Dorine, van Leeuwen, Ester M. M., Bontkes, Hetty J., Kootstra, Neeltje A., Zweegman, Sonja, Kater, Arnon P., Heemskerk, Mirjam H. M., and Groen, Kaz

Published
2022
Full Text
View/download PDF

43. Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study

Author

Toffoli, Elisa C., Sweegers, M.G., Bontkes, Hetty J., Altenburg, Teatske M., Verheul, H.M.W., Vliet, Hans J. van der, Gruijl, Tanja D. de, Buffart, L.M., Toffoli, Elisa C., Sweegers, M.G., Bontkes, Hetty J., Altenburg, Teatske M., Verheul, H.M.W., Vliet, Hans J. van der, Gruijl, Tanja D. de, and Buffart, L.M.

Abstract

Contains fulltext : 235002.pdf (Publisher’s version ) (Open Access)

Published
2021

44. The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned

Author

Nagy, Eszter, Nagy, Eszter, Infantino, Maria, Bizzaro, Nicola, Andreeva, Hristina, Bontkes, Hetty J, Bossuyt, Xavier, Fabien, Nicole, Fischer, Katarzyna, Heijnen, Ingmar A F M, Herold, Manfred, Kozmar, Ana, Kuhi, Liisa, López-Hoyos, Marcos, Pullerits, Rille, Sousa, Maria Jose Rego, Tsirogianni, Alexandra, Damoiseaux, Jan, European Autoimmunity Standardisat, Nagy, Eszter, Nagy, Eszter, Infantino, Maria, Bizzaro, Nicola, Andreeva, Hristina, Bontkes, Hetty J, Bossuyt, Xavier, Fabien, Nicole, Fischer, Katarzyna, Heijnen, Ingmar A F M, Herold, Manfred, Kozmar, Ana, Kuhi, Liisa, López-Hoyos, Marcos, Pullerits, Rille, Sousa, Maria Jose Rego, Tsirogianni, Alexandra, Damoiseaux, Jan, and European Autoimmunity Standardisat

Abstract

INTRODUCTION: The first wave of COVID-19 pandemic has disrupted almost all areas of the health care services to some extent throughout the world. Although the negative impact of COVID-19 on patients with autoimmune diseases has also been recognized, available data in this regard are limited. In the current study of the European Autoimmunity Standardisation Initiative (EASI) we aimed to provide reliable data on the extent of the impact of COVID-19 pandemic on test requests for different autoantibodies in European countries.METHODS: Data on test numbers and on the number of positive results were collected in 97 clinical laboratories from 15 European countries on a monthly basis for the year before (2019) and the year during (2020) the COVID-19 pandemic.RESULTS: A reduction in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019. The reduction affected all autoantibody tests with an overall decrease of 13%, ranging from 1.4% (Switzerland) to 25.5% (Greece). In all countries, the decrease was most pronounced during the first wave of the pandemic (March-May 2020) with an overall decrease in those three months of 45.2%. The most affected autoantibodies were those commonly requested by general practitioners (anti-tTG IgA (-71%), RF IgM (-66%) and ACPA (-61%)). In the second wave of the pandemic (October-December 2020) the decrease was less pronounced (6.8%). With respect to the rate of positive results, subtle differences were observed for distinct autoantibodies during the pandemic, but the total rate of positive results was similar in both years.CONCLUSIONS: Our study demonstrated a strong decrease in autoantibody requests during the first wave of the COVID-19 pandemic in 15 European countries. The second wave was characterized by a less pronounced impact, with some participating countries hardly affected, while some other countries experienced a second decline. The decrease was clearly associat

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results